Literature DB >> 19734311

The glycerol-3-phosphate permease GlpT is the only fosfomycin transporter in Pseudomonas aeruginosa.

Alfredo Castañeda-García1, Alexandro Rodríguez-Rojas, Javier R Guelfo, Jesús Blázquez.   

Abstract

Fosfomycin is transported into Escherichia coli via both glycerol-3-phosphate (GlpT) and a hexose phosphate transporter (UhpT). Consequently, the inactivation of either glpT or uhpT confers increased fosfomycin resistance in this species. The inactivation of other genes, including ptsI and cyaA, also confers significant fosfomycin resistance. It has been assumed that identical mechanisms are responsible for fosfomycin transport into Pseudomonas aeruginosa cells. The study of an ordered library of insertion mutants in P. aeruginosa PA14 demonstrated that only insertions in glpT confer significant resistance. To explore the uniqueness of this resistance target in P. aeruginosa, the linkage between fosfomycin resistance and the use of glycerol-3-phosphate was tested. Fosfomycin-resistant (Fos-R) mutants were obtained in LB and minimal medium containing glycerol as the sole carbon source at a frequency of 10(-6). However, no Fos-R mutants grew on plates containing fosfomycin and glycerol-3-phosphate instead of glycerol (mutant frequency, < or = 5 x 10(-11)). In addition, 10 out of 10 independent spontaneous Fos-R mutants, obtained on LB-fosfomycin, harbored mutations in glpT, and in all cases the sensitivity to fosfomycin was recovered upon complementation with the wild-type glpT gene. The analysis of these mutants provides additional insights into the structure-function relationship of glycerol-3-phosphate the transporter in P. aeruginosa. Studies with glucose-6-phosphate and different mutant derivatives strongly suggest that P. aeruginosa lacks a specific transport system for this sugar. Thus, glpT seems to be the only fosfomycin resistance mutational target in P. aeruginosa. The high frequency of Fos-R mutations and their apparent lack of fitness cost suggest that Fos-R variants will be obtained easily in vivo upon the fosfomycin treatment of P. aeruginosa infections.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19734311      PMCID: PMC2772468          DOI: 10.1128/JB.00748-09

Source DB:  PubMed          Journal:  J Bacteriol        ISSN: 0021-9193            Impact factor:   3.490


  42 in total

Review 1.  Plasmid-encoded fosfomycin resistance.

Authors:  J E Suárez; M C Mendoza
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

2.  Two kinds of mutants defective in multiple carbohydrate utilization isolated from in vitro fosfomycin-resistant strains of Escherichia coli K--12.

Authors:  T Tsuruoka; A Miyata; Y Yamada
Journal:  J Antibiot (Tokyo)       Date:  1978-03       Impact factor: 2.649

3.  UhpT, the sugar phosphate antiporter of Escherichia coli, functions as a monomer.

Authors:  S V Ambudkar; V Anantharam; P C Maloney
Journal:  J Biol Chem       Date:  1990-07-25       Impact factor: 5.157

Review 4.  Fosfomycin trometamol.

Authors:  D S Reeves
Journal:  J Antimicrob Chemother       Date:  1994-12       Impact factor: 5.790

5.  Transcription activation at the Escherichia coli uhpT promoter by the catabolite gene activator protein.

Authors:  T J Merkel; J L Dahl; R H Ebright; R J Kadner
Journal:  J Bacteriol       Date:  1995-04       Impact factor: 3.490

6.  Four new derivatives of the broad-host-range cloning vector pBBR1MCS, carrying different antibiotic-resistance cassettes.

Authors:  M E Kovach; P H Elzer; D S Hill; G T Robertson; M A Farris; R M Roop; K M Peterson
Journal:  Gene       Date:  1995-12-01       Impact factor: 3.688

7.  Synergy of fosfomycin with beta-lactam antibiotics against staphylococci and aerobic gram-negative bacilli.

Authors:  N X Chin; N M Neu; H C Neu
Journal:  Drugs Exp Clin Res       Date:  1986

8.  Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center.

Authors:  O Ciofu; B Giwercman; S S Pedersen; N Høiby
Journal:  APMIS       Date:  1994-09       Impact factor: 3.205

9.  Pi exchange mediated by the GlpT-dependent sn-glycerol-3-phosphate transport system in Escherichia coli.

Authors:  C M Elvin; C M Hardy; H Rosenberg
Journal:  J Bacteriol       Date:  1985-03       Impact factor: 3.490

Review 10.  Lung infections associated with cystic fibrosis.

Authors:  Jeffrey B Lyczak; Carolyn L Cannon; Gerald B Pier
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132

View more
  36 in total

Review 1.  Resistance to antibiotics targeted to the bacterial cell wall.

Authors:  I Nikolaidis; S Favini-Stabile; A Dessen
Journal:  Protein Sci       Date:  2014-01-17       Impact factor: 6.725

2.  Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms.

Authors:  María Díez-Aguilar; María Isabel Morosini; Emin Köksal; Antonio Oliver; Miquel Ekkelenkamp; Rafael Cantón
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

3.  Characterization of a novel two-component regulatory system, HptRS, the regulator for the hexose phosphate transport system in Staphylococcus aureus.

Authors:  Joo Youn Park; Jong Wan Kim; Bo Youn Moon; Juyeun Lee; Ye Ji Fortin; Frank W Austin; Soo-Jin Yang; Keun Seok Seo
Journal:  Infect Immun       Date:  2015-02-02       Impact factor: 3.441

4.  Deciphering the Resistome of the Widespread Pseudomonas aeruginosa Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing.

Authors:  Gabriel Cabot; Carla López-Causapé; Alain A Ocampo-Sosa; Lea M Sommer; María Ángeles Domínguez; Laura Zamorano; Carlos Juan; Fe Tubau; Cristina Rodríguez; Bartolomé Moyà; Carmen Peña; Luis Martínez-Martínez; Patrick Plesiat; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

5.  Determinants of Genetic Diversity of Spontaneous Drug Resistance in Bacteria.

Authors:  Alejandro Couce; Alexandro Rodríguez-Rojas; Jesús Blázquez
Journal:  Genetics       Date:  2016-05-10       Impact factor: 4.562

6.  Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain.

Authors:  Ester Del Barrio-Tofiño; Carla López-Causapé; Gabriel Cabot; Alba Rivera; Natividad Benito; Concepción Segura; María Milagro Montero; Luisa Sorlí; Fe Tubau; Silvia Gómez-Zorrilla; Nuria Tormo; Raquel Durá-Navarro; Esther Viedma; Elena Resino-Foz; Marta Fernández-Martínez; Claudia González-Rico; Izaskun Alejo-Cancho; Jose Antonio Martínez; Cristina Labayru-Echverria; Carlos Dueñas; Ignacio Ayestarán; Laura Zamorano; Luis Martinez-Martinez; Juan Pablo Horcajada; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

7.  Fosfomycin and tobramycin in combination downregulate nitrate reductase genes narG and narH, resulting in increased activity against Pseudomonas aeruginosa under anaerobic conditions.

Authors:  Gerard McCaughey; Deirdre F Gilpin; Thamarai Schneiders; Lucas R Hoffman; Matt McKevitt; J Stuart Elborn; Michael M Tunney
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

8.  Fosfomycin enhances the active transport of tobramycin in Pseudomonas aeruginosa.

Authors:  David L MacLeod; Jyoti Velayudhan; Thomas F Kenney; Joseph H Therrien; Jennifer L Sutherland; Lynn M Barker; William R Baker
Journal:  Antimicrob Agents Chemother       Date:  2012-01-09       Impact factor: 5.191

9.  Blocking peptidoglycan recycling in Pseudomonas aeruginosa attenuates intrinsic resistance to fosfomycin.

Authors:  Marina Borisova; Jonathan Gisin; Christoph Mayer
Journal:  Microb Drug Resist       Date:  2014-05-12       Impact factor: 3.431

10.  Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections.

Authors:  Alexandro Rodríguez-Rojas; María D Maciá; Alejandro Couce; Cristina Gómez; Alfredo Castañeda-García; Antonio Oliver; Jesús Blázquez
Journal:  PLoS One       Date:  2010-04-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.